Megazon (Quetiapine)

Quetiapine works by blocking several neurotransmitter receptors, chiefly serotonin 5‑HT₂A and dopamine D₂, which helps reduce psychotic and mood symptoms. Its additional antagonism of histamine H₁ and adrenergic α₁ receptors contributes to sedation and blood‑pressure effects.

The appropriate dose of Megazon is determined by the prescribing clinician based on the specific diagnosis, severity of symptoms, patient age, renal and hepatic function, and individual tolerability. Dosage adjustments are made during treatment as needed.

Safety data for quetiapine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made in consultation with a qualified healthcare professional.

To order Megazon, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Megazon belongs to the same class as other atypical antipsychotics such as risperidone and olanzapine. While all share dopamine and serotonin receptor antagonism, quetiapine is noted for its relatively lower risk of extrapyramidal symptoms but higher propensity for sedation and metabolic changes.

Megazon should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from excess moisture and direct sunlight to maintain stability and potency throughout its shelf life.

Megazon is taken orally as a tablet. Patients should swallow the tablet whole with water, with or without food, as directed by their prescriber. Dosing time (morning or evening) may be adjusted to minimise sedation.

Serious risks include neuroleptic malignant syndrome, agranulocytosis, severe orthostatic hypotension, and the potential for suicidal thoughts, especially when initiating therapy or adjusting dose. Prompt medical attention is required if any of these events occur.

Megazon should not be used by individuals with known hypersensitivity to quetiapine or any of its excipients, and it is contraindicated in patients taking strong CYP3A4 inhibitors that cannot be discontinued. Caution is also advised for patients with uncontrolled cardiovascular disease, severe hepatic impairment, or a history of severe psychiatric reactions.